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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration of cognitive abilities,
amyloid-b peptide (Ab) accumulation and synaptic alterations. Previous studies indicated that hyperforin, a component of the
St John’s Wort, prevents Ab neurotoxicity and some behavioral impairments in a rat model of AD. In this study we examined the
ability of tetrahydrohyperforin (IDN5607), a stable hyperforin derivative, to prevent the cognitive deﬁcit and synaptic impairment
in an in vivo model of AD. In double transgenic APPswe/PSEN1DE9 mice, IDN5706 improves memory and prevents the
impairment of synaptic plasticity in a dose-dependent manner, inducing a recovery of long-term potentiation. In agreement with
these ﬁndings, IDN5706 prevented the decreaseinsynaptic proteins inhippocampusand cortex. In addition, decreased levels of
tau hyperphosphorylation, astrogliosis, and total ﬁbrillar and oligomeric forms of Ab were determined in double transgenic mice
treated withIDN5706.In cultured cells,IDN5706decreasedthe proteolytic processingofthe amyloid precursorproteinthatleads
to Ab peptide generation. These ﬁndings indicate that IDN5706 ameliorates AD neuropathology and could be considered
of therapeutic relevance in AD treatment.
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Introduction
Alzheimer’s disease (AD) is characterized by a progressive
deterioration of cognitive abilities, eventually leading to the
death of the individual. Accumulation of the amyloid-b peptide
(Ab), a product of the processing of the amyloid precursor
protein (APP), is believed to have a key role in the cognitive
deﬁcits observed in AD.
1 Although, the mechanisms involved
in the pathogenic changes triggered by Ab are not clearly
understood, the neuronal dysfunction and cytoskeletal
alterations are early manifestations that lead to aberrant
remodeling of dendrites and axons, synaptic loss,
2 and
eventually progressive loss of neuronal populations,
3 which
is associated with the appearance of dystrophic neurites and
abnormal phosphorylation of cytoskeletal proteins mostly
phosphorylation of the microtubule-associated protein tau.
3,4
Besides, analyses of AD mouse models and AD patients
brains support the hypothesis that aggregates of Ab are
responsible for the ‘synaptic failure’, which occurs before the
plaque development and neuronal cell death; such effects
are triggered by Ab oligomers, which are soluble and toxic
molecular forms of Ab.
5,6 The synaptic failure is correlated
with the reduction in synaptic proteins and alterations in
synaptic function.
7–11
Hyperforin, the active molecule for the anti-depressant
activity of St John’s Wort (Hypericum perforatum)
12 has
been suggested to have the capacity to enhance memory in
rodents.
13 Previously, we had shown that hyperforin reduces
the behavioral alteration induced by intra-hippocampal
injection of Ab ﬁbrils in an acute rat model of AD.
14
Tetrahydrohyperforin (IDN5706) a semi synthetic derivative
of hyperforin, with a higher stability and increased oral
bioavailability,
15 has also shown some neuroprotective
properties.
16
In this study, we examined the effects of IDN5706 in vivo on
Ab neurotoxicity using young transgenic mice APPswe/
PSEN1DE9 in order to seek whether or not we can prevent
the development of the neuropathology. Five-month-old
transgenic mice were treated for 10 weeks, tested for spatial
memory and their brains were used for biochemical, histo-
chemical and electrophysiological analysis. We report
here that IDN5706 signiﬁcantly reduces the spatial memory
impairments, tau hyperphosphorylation, Ab oligomer accu-
mulation and increases long-term potentiation (LTP),
Received 2 June 2011; accepted 3 June 2011
1Centro de Envejecimiento y Regeneracio ´n (CARE), Santiago, Chile;
2Departamento de Biologı ´a Celular y Molecular, Facultad de Ciencias Biolo ´gicas, P. Universidad
Cato ´lica de Chile, Santiago, Chile and
3Instituto de Fisiologı ´a, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile
Correspondence: Dr NC Inestrosa, CARE Center P. Universidad Cato ´lica de Chile, Santiago 8331150, Chile.
E-mail: ninestrosa@bio.puc.cl
4Present address: Graduate School, Neuroscience PhD Program, Northwestern University, Evanston, IL.
Keywords: APP transgenic; Ab neurotoxicity; Hypericum perforatum; IDN5706; LTP; PHF-1 phosphorylation
Citation: Transl Psychiatry (2011) 1, e20, doi:10.1038/tp.2011.19
& 2011 Macmillan Publishers Limited All rights reserved 2158-3188/11
www.nature.com/tpsuggesting the availability of a new pharmacological tool to
ﬁght against AD.
Materials and methods
Reagents and antibodies. Tetrahydrohyperforin (IDN5706)
was obtained from Indena SpA, Milan, Italy. Tetrahydro-
phyperforin is a semi synthetic derivative of hyperforin (WO
03/091194 A1; WO 2004/106275 A2). Primary antibodies
used are as follows: rabbit anti-glial ﬁbrillar acidic protein
(DAKO, Denmark), mouse anti-Ab (4G8, Chemicon,
Temecula, CA, USA), goat anti-synaptophysin, rabbit
polyclonal anti-b-tubulin, rabbit anti-tubulin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and mouse anti tau
epitope paired-helical ﬁlament1 (PHF-1). The monoclonal
antibodies anti-PSD95, anti-NR2B and anti-VGlut1 were
developed by and obtained from the UC Davis/NIH
NeuroMab Facility (Davis, CA, USA).
Animals. APPswe/PSEN1DE9 mice, which express the
mutant APPSWE (K595N/M596L) and PSEN1DE9, deletion
of the exon 9 (APP-PS1 mice stock 004462) were obtained
from Jackson Laboratory (Bar Harbor, ME, USA).
Treatments were performed by i.p. injection of IDN5706
with solutol as vehicle, initiated at 5 months of age and
continued three times a week per 10 weeks. Transgenic and
wild-type control animals were injected with the vehicle.
Behavioral test. The Morris water maze was performed as
previously described in our laboratory.
17,18
Slice preparation and electrophysiology. Hippocampal
slices were prepared according to the standard procedures
previously described in our laboratory.
19 To generate LTP we
used high-frequency stimulation (HFS), three trains of
500ms stimuli at 100Hz with a 20-s interval. Recordings
were ﬁltered at 2.0–3.0kHz, sampled at 4.0kHz using an A/D
converter, and stored with pClamp 10 (Molecular Devices,
Sunnyvale, CA, USA). Evoked postsynaptic responses were
analyzed off-line, using an analysis software (pClampﬁt,
Molecular Devices), which allowed visual detection of events,
computing only those events that exceeded and arbitrary
threshold.
Immunohistochemical procedures. Perfusion, ﬁxation
and free-ﬂoating immunohistochemical procedures were
performed as previously described.
17,18,20 Image analysis
and PHF-1 neuronal counting were carried out as previously
described.
17,20
Thioﬂavine S (ThS) staining. ThS staining was developed
in sections mounted on gelatin-coated slices as previously
described.
17,18
Immunoblotting. The hippocampus and cortex of treated
or control transgenic mice were dissected on ice and
immediately frozen at  1501C or processed. Immuno-
blotting and slot blot assays were performed as previously
described.
17,21
H4 neuroglioma transfection. For C99-EGFP, the
sequence encoding C99 with a signal peptide was cloned
by PCR using as a template C99-GFP kindly provided by
Dr Christian Haass and cloned in frame into XhoI and SalI
sites of pEGFP-N1. Transfections of H4 neuroglioma cells
were carried out using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) for 1h at 371C in the absence of FBS
and 16h post-transfection cells were incubated at different
times with 100–500mM IDN-5706, 250nM DAPT (Sigma-
Aldrich, St Louis, MO, USA), 150mgml
 1 CHX (Sigma-
Aldrich) and 40mgml
 1 chloramphenicol (Sigma-Aldrich).
Statistical analysis. Data analysis was carried out with
Prism software (GraphPad Software, La Jolla, CA, USA).
Results were expressed as mean±s.e. For statistical
analysis, normally distributed data were analyzed by one-
way ANOVA with post hoc tests performed using the Tukey
test. Non-normally distributed data were analyzed by the
Kruskal–Wallis test with post hoc tests performed using
Dunn’s test.
Results
IDN5706 treatment decreased Ab burden, tau
hyperphosphorylation and astrogliosis in double
transgenic APPswe/PSEN1DE9 mice. Double transgenic
mice that express the mutant APPSWE (K595N/M596L)
and PS1 (PSEN1DE9: deletion of the exon 9) generate
Ab plaques in both the cortex and hippocampus in an age-
and region-dependent manner.
22 To analyze the effect of
IDN5706 on physiopathological markers of AD, 5-month-old
double transgenic APPswe/PSEN1DE9 mice (APP-PS1)
were injected i.p. with 4mgkg
 1 IDN5706 or vehicle
(control) three times a week per 10 weeks. By staining with
an antibody against total Ab, we ﬁrst analyzed Ab burden in
the cortex and hippocampus (Figure 1a). A signiﬁcant
reduction in Ab burden was observed in IDN5706-treated
mice as measured by the area positive for Ab aggregates
(Figure 1b). IDN5706 also decreased the amount of Ab sheet
burden measured by ThS staining (Supplementary Figure 1).
These results indicate that IDN5706 prevents Ab load in the
transgenic mouse model.
Apparently, Ab oligomers are responsible for the synaptic
dysfunction observed in AD patients and mice models.
5
We determined the relative amount of Ab oligomers by slot
blotusingthespeciﬁcantibodyA11aspreviouslydescribed.
23
Brain extracts from APP-PS1 mice treated with 4mgkg
 1
IDN5706 for 10 weeks showed a reduction in the relative
amount of Ab oligomers in both hippocampus and cortex
comparedwithcontrolAPP-PS1miceinjectedwiththevehicle
solution (Figure 1c), indicating that IDN5706 reduces
the amount of synaptotoxic Ab oligomers present in AD mice
brains.
The phosphorylation of tau, particularly the appearance
of the epitope PHF-1 (phosphorylated Ser-396 and Ser-404),
was analyzed nearby Ab plaques stained with ThS
(Figure 1d). Although tau phosphorylation affects different
parts of the hippocampus and cortex, we choose to evaluate
PHF-1-positive cells in a circular area (r¼100mm) surround-
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Translational Psychiatrying amyloid plaques
20 as it has been described that
cytoskeletal changes, tau phosphorylation, glial ﬁbrillar acidic
protein activation and synapses loss occurs mainly in these
areas.
2,20,24 Treatment with IDN5706 induced Ban 80%
decrease in the number of PHF-1-positive neurons next to
amyloid deposits (Figures 1d, middle panels, and Figure 1e).
Although few PHF-1-positive cells were found outside
the circular area around the plaques (Figure 1d, bottom
panels), we analyzed total PHF-1-positive cells per area
(cortexþhippocampus)anddeterminedastrongdecreaseby
IDN5706 treatment (Figure 1f).
The astroglial inﬂammatory reaction is another pathological
change characteristic of AD brains.
25 APP-PS1 mice show
higher staining for the marker of astroglial inﬂammatory
reaction glial ﬁbrillar acidic protein than age-matched wild-
type animals (Supplementary Figure 2A), and this staining
was signiﬁcantly reduced in the hippocampus and cortex
of IDN5706-treated APP-PS1 mice. IDN5706 treatment
also reduced perikaryon enlargement in hippocampus
(Supplementary Figure 2B) and cortex (Supplementary
Figure 2C), indicating that IDN5706 prevents the neuro-
inﬂammatory reaction characteristic of AD.
Figure 1 IDN5706 reduces the total amount of Ab, the levels of Ab oligomers and the number of PHF-1-positive neurons in brains of APP-PS1 mice. (a) Total Ab
aggregates in control APP-PS1 trangenics (Tg control) and in IDN5706-treated brains (TgþIDN5706). Tg control mice were injected i.p. with vehicle solution and
TgþIDN5706were injected with 4mgkg
 1 IDN5706 threetimes a week per 10 weeks.(b) Average areafraction positivefor Ab. Bars representthe averageplaque area for
the treatment±s.e. (n¼4). (c) Representative slot blot from hippocampal and cortical fractions using 6mg protein per slot spotted into a nitrocellulose membrane and
expose to A11 antibody. Graphs represent normalized densitometric analysis proﬁle of the slot intensity for each treatment. (d) Images show representative detection of
PHF-1-positive cells (left panels) near amyloid plaques detected with ThS (right panels). Positive neurons are indicated by black arrows and the amyloid plaques by a white
arrow. Bottom panels show that no PHF-1-positive cells are detected in other regions. (e, f) The graphs show the quantiﬁcation of the number of PHF-1-positive neurons per
plaque (e) and per area in 0.03mm
2 (f). Bars represent the mean±s.e (nX3). *Po0.05; **Po0.01; ***Po0.001.
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Translational PsychiatryAb burden and tau phosphorylation was also evaluated
in APP-PS1 mice injected i.p. with different concentrations of
IDN5706. Treatment with 2, 4 and 6mgkg
 1 IDN5706
reduced Ab burden, as assessed by staining with an antibody
against total Ab (Figures 2a and b) and Ab sheet burden
measured by ThS staining (Figure 2c and Supplementary
Figure 3). Tau phosphorylation in Ser-396 and Ser-404
(PHF-1 antibody) and in Ser-202 residue (AT8 antibody)
wasassessedbyimmunoblotting.Adose-dependentdecrease
in both epitopes was observed in the hippocampi of APP-PS1
mice (Figure 2d). In agreement with the reduced phosphor-
ylation of tau, treatment with IDN5706 increased the levels of
the inactive form of GSK-3b that is phosphorylated in serine 9
residue (Figure 2e).
Treatment with IDN5706 enhances the spatial learning
in wild-type mice and prevents the spatial memory loss
in APP-PS1 mice. The effect of IDN5706 on hippocampal
Figure 2 Dose-dependentdecreaseofAb depositsandtauphosphorylationin APP-PS1 mice.(a)TotalAbaggregatesincontrolAPP-PS1trangenics(Tg control)andin
Tgtreatedwith2,4and6mgkg
 1IDN5706for10 weeks.(b,c)AverageareafractionpositiveforAb(b)oramyloidplaquesdetectedwithThSstaining(c)inbrainsofcontrol
and IDN5706-treated APP-PS1 mice. (d) Immunoblot of total brain homogenates from APP-PS1 mice injected i.p. with vehicle solution or 2, 4 and 6mgkg
 1 IDN5706 three
timesaweekper10weeksusingthePHF-1andAT8antibody.(e)Thegraphshowsthedensitometricanalysisofbandsnormalizedagainstb-actinandcomparedwithcontrol
APP-PS1. Total and phosphorylated GSK-3b was also detected. The levels of GSK-3b phosphorylated in serine 9 were normalized against total GSK-3b levels. Bars
represent the mean±s.e (nX3). *Po0.05; **Po0.01; ***Po0.001.
IDN5706 prevents memory and synaptic impairment in AD mice
NC Inestrosa et al
4
Translational Psychiatryfunction was assessed in APP-PS1 mice that were injected
i.p. with different doses of IDN5706 or vehicle since 5-month-
old, three times a week per 10 weeks. Hippocampal function
was assessed in the Morris water maze spatial memory
test.
26 In this task, mice are required to learn the location of a
hidden platform by external cues. Wild-type animals treated
with IDN5706 presented lower escape latency values
compared with wild-type controls injected with the vehicle
solution (Figure 3a). These differences were signiﬁcant only
during the ﬁrst week of training, which indicates an
improvement in the short-term memory (Figure 3b). On the
other hand, APP-PS1 mice treated with all concentrations of
IDN5706 showed lower latency times to reach the platform
than control APP-PS1 mice (Figure 3c, Supplementary
Table 1). There was a concentration-dependent decrease
in the escape latency, being in animals treated with
6mgkg
 1 almost similar to that of wild-type animals
(Figure 3c). The behavioral improvement was observed
after 4 and 5 days of testing (short-term memory) and also
between 8 and 10 days (long-term memory). This effect is
also observed in the distance of the swimming path to reach
the platform (Figure 3d, Supplementary Table 2). APP-PS1
mice treated with IDN5706 had a signiﬁcantly reduced
swimming path than control APP-PS1 mice, suggesting an
improvement in the hippocampal function. These results
indicate that IDN5706 is able to prevent the deﬁcit in spatial
memory that appeared in APP-PS1 transgenic mice and in a
dose-dependent manner.
IDN5706 induces an increase in LTP in hippocampal
slices from transgenic mice. The behavioral improvement
in the Morris water maze could by explained by an effect of
IDN5706 on synaptic activity, it is likely possible that there is
a recovery or generation of a robust LTP. We explored the
effects of IDN5706 on ﬁeld excitatory postsynaptic potentials
(fEPSP), in hippocampal slices incubated with different
concentrations of IDN5706. LTP was generated using
HFS (100hz, 500ms, three times). In APP-PS1 mice, a
decreased response to the HFS was observed compared
with age-matched wild-type animals (Figure 4a). A dose-
dependent recovery of LTP was observed in transgenic mice
treated with IDN5706. Slices from mice treated with 2 and
4mgkg
 1 IDN5706 show fEPSP similar to 8-month-old wild-
type animals (Figure 4a). Moreover, slices from transgenic
animals treated with 6mgkg
 1 IDN5706 show a stronger
LTP than wild-type hippocampal slices of 8-month-old mice
(Figure 4b). These results suggest that IDN5706 facilitates
LTP induction in double transgenic APP-PS1 mice.
IDN5706 prevents the decrease in synaptic
proteins. Synaptic disturbances are present in AD brains,
as well as in transgenic AD models.
7,8,11,27 We carried out a
detailed analysis of synaptic proteins affected in APP-PS1
mice. As presynaptic markers, the levels of the synaptic
vesicle protein synaptophysin and VGlut1 were evaluated.
28
As postsynaptic markers, the levels of the NMDA receptor
subunit NR2B, the AMPA receptor subunit GluR2 and the
Figure 3 Treatment with IDN5706 enhances the spatial learning in wild-type mice and reduces the spatial memory impairment in APP-PS1 mice. Mice were injected i.p.
withvehiclesolutionor2,4and6mgkg
 1IDN5706threetimesaweekper10weeks.SpatialmemorywasevaluatedintheMorriswatermaze.(a)Escapelatencyofwild-type
mice to reach the hidden platform was reduced by IDN5706 treatment. (b) The statistical analysis of escape latency of wild-type mice shows signiﬁcant differences in the ﬁrst
weeks of training. (c) Higher escape latency during the test was shown by control APP-PS1 compared with vehicle-injected wild-type animals, and the escape latency was
reducedin IDN5706-treated animals in a dose-dependent manner. (d) Analysis of the swimmingpath of APP-PS1 micecompared with wild-type animals. Reduced distances
to reach the platform were observed in APP-PS1 mice treated with increasing doses of IDN5706. Statistical analyses are shown in Supplementary Tables 1 and 2. *Po0.05;
**Po0.01; ***Po0.001.
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Translational Psychiatrypostsynaptic density protein PSD-95 were evaluated.
29
APP-PS1 animals show reduced levels of most of the
synaptic proteins evaluated (VGlut1, GluR2, PSD-95 and
NR2B) in the hippocampus and cortex as compared with
age-matched wild-type animals (Figures 4c,d). Treatment with
IDN5706 prevented the decrease of postsynaptic markers
observed in APP-PS1 mice. In the hippocampus of IDN5706-
treated animals there was a signiﬁcant protection in total
levels of GluR2 and PSD-95 (Figure 4c), while the cortex
showed higher levels of these two proteins and also of NR2B
and VGlut1 (Figure 4d). These results indicate that IDN5706
is able to prevent the synaptic protein loss observed in
APP-PS1 mice.
IDN-5706 inhibits C99 c-secretase proteolytic
processing. Finally, and in an attempt to explore the
potential mechanism involved in the neuroprotective effect
of IDN5706, we analyzed whether IDN5706 affects the
proteolytic processing that leads to Ab peptide generation.
Because a small percentage of APP is cleaved by
b-secretase, we examined the effect of IDN5706 using a
recombinant EGFP-tagged C99 construct (C99-EGFP) that
mimics b-secretase-cleaved APP. This system conveniently
allows us to characterize all proteolytic events that tightly
control C99 levels and thus, Ab peptide generation. This
includes: (i) g-secretase cleavage that results in release of
Ab into the extracellular space and of the APP intracellular
domain (AICDg) into the cytosol; (ii) a-secretase cleavage
that mediates conversion of C99 to C83, thus reducing
Ab peptide production; (iii) and caspase cleavage leading to
the production of cytosolic C31 (Figure 5a). Immunoblotting
for C99-EGFP in H4 neuroglioma cells, a well-established
model system for biochemical analysis of C99 processing,
30
showed four species corresponding to C99, C83, AICDg and
C31 (Figure 5b). This result indicates that this construct is
indeed processed by all the corresponding enzymatic
activities, conﬁrming our previous ﬁndings
30 (Figure 5b).
Increasing concentrations of IDN5706 for 8h resulted in a
dramatic decrease in AICDg levels (Figure 5b). At 100mM
IDN5706, AICDg decreased to a 40% the level present in
Figure 4 IDN5706 improves LTP in hippocampal slices from APP-PS1 mice in a dose-dependent manner and prevents the reduction of synaptic proteins in APP-PS1
mice. (a) LTP generated by HFS in hippocampal slices from wild-type mice, control APP-PS1 and APP-PS1 mice treated with 2, 4 or 6mgkg
 1 of IDN5706. Quantiﬁcation of
fEPSPamplitudeisshown.(b)PlotoffEPSPamplitudeafter60minofHFSinhippocampalslicesfromwild-typemice,controlAPP-PS1andAPP-PS1micetreatedwith2,4or
6mgkg
 1 of IDN5706. The graph shows the mean±s.e from six independent experiments. *Po0.05, compared with APP-PS1 mice. (c, d) Representative immunoblots of
total protein extracts from hippocampus (c) and cortex (d) of wild-type (WT, gray bars) and APP-PS1 (Tg, white bars) and APP-PS1 mice treated with IDN5706 (black bars).
Graphscorrespondtothedensitometricanalysisofeachproteinnormalizedagainstb-tubulinandcomparedwiththelevelsofthesameproteininWTmice(n¼4).*Po0.05;
**Po0.01; ***Po0.001.
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Translational Psychiatryuntreated cells, with a maximum decrease to a 6% in cells
incubated with 500mM IDN5706. Cells incubated with 500mM
IDN5706 at different times showed that after 2h AICDg
generation decreased 40%, with the greatest reduction
between 6 and 8h (Figure 5c). This reduction in AICDg
level was similar to that obtained with 250nM DAPT, a
speciﬁc inhibitor of g-secretase activity (Figure 5c).
No signiﬁcant effect on the levels of C83 and C31 was
observed (Figures 5b,c). Because it is well known that
g-secretase inhibition by DAPT leads to a delay in C99
turnover, we studied whether treatment with IDN5706 might
also produce a similar outcome. H4 neuroglioma cells
expressing C99-EGFP were preincubated with 500mM
IDN5706 for 8h and then a combination of cycloheximide
and chloroamphenicol was added to stop translation at
different periods of time, with or without 500mM IDN5706
(Figure 5d). Control cells showed a short half-life of 20min for
C99 (Figure 5d, lanes 1–4). In contrast, treatment with
IDN5706 resulted in a dramatic delay in the turnover of C99
(Figure 5d, lanes 5–8). Altogether these data suggest that
IDN5706 affects the processing of C99 probably by inhibition
of g-secretase cleavage.
Discussion
In this study, we have demonstrated that 5-month-old
APP-PS1 mice treated with tetrahydrohyperforin, IDN5706,
during 10 weeks did not present decreased cognitive
capacities and neuropathological markers of AD as compared
with control vehicle-injected APP-PS1 mice. Speciﬁc neuro-
protective effects of IDN5706 observed in this study include:
reduction in total ﬁbrillar and oligomeric forms of Ab, reduction
in the levels of tau hyperphosphorylation and astrogliosis, and
prevention of synaptic protein loss. Moreover, in IDN5706-
treated animal it was possible to induce LTP by HFS.
In neuroglioma cells, IDN5706 reduced the processing of
APP that conducts to Ab peptide generation. Taken together,
our data indicate that IDN5706 might be of therapeutic
relevance in AD.
A previous study in our laboratory indicated that IDN5706
was able to reduce neuropathological markers in 12-month-
old APP-PS1 mice treated with 2mgkg
 1 IDN5706 for
1 month.
16 However, in that study no reduction in total Ab
burden was found, despite a slight reduction in the size of
ThS-positive plaques. In the present work, in 5-month-old
APP-PS1 mice treated with 4mgkg
 1 IDN5706 for 10 weeks,
a reduction in the amount of total Ab burden, Ab amyloid
plaques and Ab oligomers was found. Moreover, a
dose-dependent decrease in Ab-burden was observed. Our
ﬁndings suggest that treatment of young animals with
IDN5706, previously to the time frame where the plaque
formation takes place,
31 affects the mechanism of Ab peptide
formation and/or its aggregation kinetics, resulting in a
decreased Ab burden and lower levels of Ab oligomeric
Figure 5 IDN5706 inhibits C99 proteolytic processing by g-secretase in H4 neuroglioma cells. (a) Schematic representation of C99 indicating its topological domains; the
positionoftheAbpeptide;thea,g,andcaspasecleavagesites;andthefragmentsproduced.(b,c)Anti-GFPimmunoblotanalysisfromH4neurogliomacellstransfectedwith
EGFP-tagged C99 after treatment with only IDN5706 with the variations indicated below, or in the presence of a combination of 150mgml
 1 CHX and 40mgml
 1
chloramphenicol for 0–60min. (d) The positions of molecular mass markers and different proteolytic species are indicated.
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that IDN5706 decreased the processing of APP particularly
the processing by g-secretase, supporting that the decrease
inAbformationmightberelatedtothemechanismofIDN5706
neuroprotection.Anotherpossibilitythatcouldalsoexplainthe
effect of IDN5706 in vivo could be an enhanced clearance or
disassembly of Ab aggregates. In fact, we have previously
demonstrated that IDN5706 inhibits Ab aggregation in vitro.
14
Moreover, we have shown that in vitro, hyperforin is able to
disaggregate pre-formed ﬁbrils into protoﬁbrils and amor-
phous material.
14 Taking into consideration our results, we
think that IDN5706 might have anti-amyloidogenic actions
both in vitro and also in vivo. Because IDN5706 was able
to decrease the levels of oligomeric species of Ab, its anti-
amyloidogenic mechanism did not result in a more toxic end
products. Although we have shed light into the mechanism of
actionofIDN5706,furtherinvivostudiesarenecessarytofully
clarify the molecular and cellular mechanisms involved in
the reduction of Ab aggregates by IDN5706.
In our study, IDN5706 was also shown to prevent tau
pathology, a key hallmark of AD.
32–34 Fibrils composed of
hyper-phosphorylated tau accumulate within neuronal cell
bodies and dendrites in AD brain and form the PHFs that
coalesce into neuroﬁbrillary tangles (NFTs). The propensity of
hyper-phosphorylated tau to aggregate and binds with lower
afﬁnity to MTs suggests that reducing tau phosphorylation
in AD might provide therapeutic beneﬁts. We determined
that IDN5706 reduced the number of neurons positive for
PHF-1 antibody and the total amounts of tau phosphorylated
at epitopes PHF-1 and AT8 in APP-PS1 mice brains. The
reduction of PHF-1-positive neurons could be a con-
sequence of a decreased accumulation of Ab and inﬂamma-
tory response, and also IDN5706 may have effects on the
signaling that deﬁne to trigger tau phosphorylation. Several
kinases can phosphorylate tau in vitro; however, the bulk of
the information supports that GSK-3b, Cdk5, extracellular
signal-related kinase 2 and microtubule afﬁnity-regulating
kinase are the most relevant kinases for tau phosphorylation
in vivo.
35–37 It is therefore possible that IDN5706 may be able
to regulate the activity of kinases such as GSK-3b and Cdk5.
Consistent with the role of GSK-3b, we found increased levels
of inactive GSK-3b in APP-PS1 mice treated with IDN5706.
The inhibition of the signaling associated to neuronal
damage has been shown to attenuate Ab accumulation.
For example, the inhibition of GSK-3b by lithium not only
reduces tau phosphorylation in vitro and in AD mice, but also
produces a concomitant reduction in Ab production.
38,39
Besides, GSK-3b is a negative modulator of the canonical
Wnt signaling pathway.
40 We have previously shown
decreased activity of GSK-3b in hippocampal neurons
exposed to Ab in the presence of a Wnt ligand
41 or the
pharmacologicalactivatoroftheWntpathwaylithium,
42andin
APP-PS1 mice exposed to lithium.
17 In all these cases the
inactivation of the kinase was correlated with increased Wnt
activity and neuroprotection. Whether the neuroprotective
effect of IDN5706 is associated to the activation of the
Wnt signaling pathway will have to be determined.
The Ab oligomers can negatively modulate synaptic
plasticity and memory,
8 generating failures and damage in
the synaptic cleft.
43 Previously, we showed that hippocampal
slicesexposedtoAb oligomersgenerate asynaptotoxic effect
with reduced synaptic efﬁcacy and impaired synaptic trans-
mission mainly by decreasing NMDA and AMPA receptors
currents, which could be explained by reduced levels of
PSD-95 and synaptic contacts.
44 Our present ﬁndings
indicate a positive effect of IDN5706 on LTP induction in
APP-PS1 mice. LTP is a synaptic process that occurs in
dendritic spines of neurons involved in synaptic plasticity
related to memory in some regions of the brain.
45 Different
reports have suggested a relationship between memory tests
and LTP,
46–48 therefore it is possible that the improvement of
LTPphenomenoncouldaccountfortherecoveryinthe spatial
memory of transgenic mice treated with IDN5706.
Finally, IDN5706 prevented the reduction of synaptic proteins
invivo,whichisapathologicalcharacteristicfoundinvariousAD
models.
9,49–51 IDN5706 mainly prevented the reduction in
relevant postsynaptic proteins. Interestingly, hyperforin, the
compound from which IDN5706 is derived, has various
neurobiological effects (for review, see ref. 52) which could
explain the protective effect of IDN5706 against the synapto-
toxicity observed in AD mice. For example, it is known that Ab
oligomers decrease the levels of PSD-95 in vitro,
50 and we
observed that IDN5706 decreased the amount of Ab oligomers
in vivo and also decreased the processing of APP that leads to
the generation of Ab peptide in vitro,w h i c hm i g h te x p l a i nw h y
IDN5706 exerts protective effects over PSD-95 levels.
As mentioned, IDN5706 is a semi synthetic derivative of
hyperforin which is the major active compound of SJW.
52
Whether hyperforin has the same neuroprotective effects
determined for IDN5706 will have to be determined in future
experiments. However, IDN5706 was chosen from a spec-
trum of derivatives due to its higher stability and because of
an increased oral bioavailability as compared with hyperforin
and its other derivatives,
15 thus this molecule is therapeuti-
cally more attractive than hyperforin itself.
In summary, our ﬁndings indicate that IDN5706 is able
toreduce the neuropathology inAPP-PS1 mice decreasing all
the neuropathological hallmarks studied. More importantly,
IDN5706 ameliorates the impairment of memory and synaptic
plasticity associated to AD pathology. These ﬁndings strongly
suggest a therapeutic potential of IDN5706 for the treatment
of AD.
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